Looking to collaborate?
What does your test detect?
What infection type does your test focus on?
What is the technological basis of your test?
About this entry
AgPlus has a strong technical, operational and commercial team with extensive experience in electrochemistry, immunoassay product development and commercialisation.
AgPlus’s core area of expertise is the electrochemistry and we have invested in the appropriate resources, equipment and facilities to manage the chemistry deposition, final packaging and product release. Our facilities are certified to ISO 13485. Our facilities at Colworth Park in Bedfordshire are set up for contract development and medium scale manufacture; we have invested in and validated chemistry deposition equipment, drying equipment controlling both humidity and temperature and semi-automated assembly equipment. Processes have been put in place for primary and secondary packaging activities. Resource commensurate with those activities is in place.
The design and manufacture of the cartridge components and the reader is key to AgPlus’s success. World class sub-contractors are used for these aspects, ensuring well established processes and facilities.
AgPlus has optimised its novel electrochemical detection PoC system, using Anodic Stripping Voltammetry, (ASV) technology pioneered and patented by the National Physical Laboratory. Proof of concept studies have been completed proving the technology gives improved analytical sensitivity and specificity over existing lab based or PoC systems. The AgPlus system is effective with various biomarkers and sample matrices. The focus in the last 12 months has been developing assays for the detection of HNL biomarker in patients with infectious disease. The technology has been progressed from a lab based wet assay system to a portable reader and dry cartridge system.
The principal work on HNL as a biomarker on patients with infection, has been undertaken by Professor Per Venge’s team at Uppsala University Hospital. AgPlus has an established relationship with that team and a commercial agreement for the supply of the antibodies that will be required.
This assay is to be used in the rapid distinction between bacterial and viral infections. The key improvements on current technology will be the reliability of assay with regards clinical sensitivity and specificity improving on current assays from @75 % to 90+%, the speed and accessibility of getting a test result near patient, convenience of a whole blood sample from a finger stick and finally affordable pricing for the reader and test system